Society of Hematologic Oncology Sixth Annual Meeting
Avatar

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, and How to Salvage Therapy

By Society of Hematologic Oncology Sixth Annual Meeting FEATURING Sundar Jagannath
October 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

10:17
Amgen Oncology

Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study

Feat. H. Kaya

Featured Video

10:17
Amgen Oncology

Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study

Feat. H. Kaya

Related Content

AUTOPLAY
Roswell Park Comprehensive Cancer Center

Plasma Cell Disorders Meeting 2019

Fri, Nov 1, 2019
International Society of Geriatric Oncology

19th Conference of the International Society of Geriatric Oncology

Thu, Nov 14, 2019
10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
19:49
Gareth J Morgan

Contemporary Design of MM Treatment: Developing New Therapeutic Endpoint...

17:03
Ajai Chari

Diagnosing Smoldering Multiple Myeloma

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Fi...

Feat. K. Anderson
05:05
Indy Hematology Review

Risk of Progression of Smoldering Myeloma to Active Multiple Myeloma

Feat. K. Anderson
09:49
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Maint...

15:02
Krina Patel

Clinical Trials in Myeloma in 2018

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple Mye...

15:11
Ajay Nooka

Early Relapse: Choosing Among Different Second Line Regimens in Myeloma

10:17
Amgen Oncology

Multiple Myeloma: Use of Proteasome Inhibitor at First Relapse-A Case Study

Feat. H. Kaya
13:26
Shaji Kumar

Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma

17:17
Society of Hematologic Oncology Sixth Annual Meeting

Emerging Data on Management and Imaging of Myeloma Bone Disease

Feat. M. Dimopoulos
17:03
Thomas Martin

Novel Clinical Trials for Smoldering Multiple Myeloma in 2018

16:22
Society of Hematologic Oncology Sixth Annual Meeting

FDA Approves Selinexor for Refractory Multiple Myeloma, STORM Study

Feat. S. Jagannath
21:40
Natalie Callander

Smoldering Myeloma: Risk Stratification and Therapeutic Options

12:32
Indy Hematology Review

What's New in Immunotherapy and Genomics in Multiple Myeloma?

Feat. K. Anderson
15:10
Krina Patel

Developing CAR T-cells in Multiple Myeloma

15:47
Society of Hematologic Oncology Sixth Annual Meeting

Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Ma...

Feat. S. Lonial